Get the Stockscreener App
11.83
2.23%
-0.27
Biohaven Ltd stock is traded at $11.83, with a volume of 1.81M.
It is down -2.23% in the last 24 hours and up +1.63% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
See More
Previous Close:
$12.10
Open:
$12.12
24h Volume:
1.81M
Relative Volume:
0.44
Market Cap:
$1.57B
Revenue:
-
Net Income/Loss:
$-766.97M
P/E Ratio:
-1.5444
EPS:
-7.66
Net Cash Flow:
$-646.43M
1W Performance:
-12.44%
1M Performance:
+1.63%
6M Performance:
-24.17%
1Y Performance:
-69.67%
1-Day Range:
$11.53
$12.29
1-Week Range:
$11.53
$13.37
52-Week Range:
$7.48
$44.28
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
11.83 | 1.61B | 0 | -766.97M | -646.43M | -7.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-21-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-26-25 | Downgrade | UBS | Buy → Neutral |
| Nov-06-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Nov-05-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Initiated | Citigroup | Buy |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Sep-16-24 | Initiated | Jefferies | Buy |
| Sep-04-24 | Initiated | Bernstein | Outperform |
| Jul-24-24 | Initiated | Morgan Stanley | Overweight |
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
Sectors Review: Can Biohaven Ltd deliver alphaJuly 2025 Volume & Weekly High Momentum Picks - baoquankhu1.vn
Biohaven Ltd. (NYSE:BHVN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Closing: Can Biohaven Ltd be recession proofWeekly Market Outlook & AI Driven Price Forecasts - baoquankhu1.vn
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 63% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
Aug Action: Is First Merchants Corporation attractive for institutional investorsEarnings Risk Summary & Real-Time Volume Triggers - baoquankhu1.vn
Jim Cramer on Biohaven: “The Stock Seems Very Low to Me” - MSN
Assessing Biohaven (BHVN) Valuation After A Sharp Momentum Rebound - Yahoo Finance
Biohaven (NYSE:BHVN) Shares Gap UpWhat's Next? - MarketBeat
This Albemarle Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
RBC Capital Upgrades Biohaven (BHVN) - Nasdaq
BHVN Upgraded by RBC Capital: New Price Target of $22 | BHVN Sto - GuruFocus
RBC Upgrades Biohaven to Outperform From Sector Perform, Boosts Price Target to $22 From $9, Keeps Speculative Risk - marketscreener.com
Biohaven stock rating upgraded by RBC Capital on promising CNS data - Investing.com South Africa
(BHVN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Biohaven (BHVN) Is Up 15.6% After Showcasing MoDE and TRAP Degrader Data in Autoimmune Diseases - simplywall.st
JPM26: After a Tough 2025, Biohaven Is Gearing Up To Challenge Goliath—Lilly - BioSpace
Assessing Biohaven (BHVN) Valuation After Positive MoDE And TRAP Degrader Clinical Updates - simplywall.st
Pomerantz To Lead Biohaven Investors' FDA Approval Suit - Law360
Biohaven (NYSE:BHVN) Stock Price Up 8%Still a Buy? - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Shares Surge 3.42% to $12.10 Amid Positive Clinical Data - Intellectia AI
Biohaven (BHVN) Stock Is Trending Overnight — Here's What You Should Know - Benzinga
BHVN SEC FilingsBiohaven 10-K, 10-Q, 8-K Forms - Stock Titan
Can Biohaven Ltd. deliver alphaMarket Weekly Review & Low Risk High Reward Ideas - bollywoodhelpline.com
Biohaven Ltd. (BHVN) Investor Outlook: Navigating Opportunities with a 68% Upside Potential - DirectorsTalk Interviews
Biohaven (NYSE:BHVN) Shares Down 6.3%Here's Why - MarketBeat
Biohaven (BHVN) Is Up 19.2% After Early Success With Selective Antibody Degraders In Kidney, Thyroid Diseases - simplywall.st
Biohaven stock maintains Outperform rating at Baird on promising IgAN data - Investing.com
Biohaven stock maintains Outperform rating at Baird on promising IgAN data By Investing.com - Investing.com South Africa
Biohaven highlights degrader platforms in new investor presentation - TipRanks
Biohaven Ltd Announces Investor Presentation on January 12, 2026 - TradingView
Biohaven reports early patient data from protein degrader programs - StreetInsider
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Early trial data hint at new options for kidney disease, thyroid, seizures - Stock Titan
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 - PR Newswire
Aug Update: Is Biohaven Ltd stock oversold or undervaluedJuly 2025 Volume & AI Driven Stock Price Forecasts - Bộ Nội Vụ
Biohaven Ltd. (BHVN) upgraded to buy: Here's what you should know - MSN
(BHVN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Jobs Data: Why Biohaven Ltd stock attracts global investorsWeekly Stock Recap & AI Based Buy/Sell Signal Reports - moha.gov.vn
Volatility Watch: Why Biohaven Ltd stock attracts global investorsEarnings Growth Summary & Real-Time Volume Triggers - moha.gov.vn
Will Biohaven Ltd. stock continue dividend increasesQuarterly Profit Review & Verified Chart Pattern Signals - Улправда
Is Biohaven Ltd. stock overvalued by current metricsMarket Risk Report & AI Forecast for Swing Trade Picks - Улправда
Will Biohaven Ltd. stock recover faster than peersTrade Volume Report & Daily Risk Controlled Trade Plans - ulpravda.ru
Aug Final Week: Is Biohaven Ltd. stock oversold or undervaluedQuarterly Portfolio Report & Long-Term Growth Stock Strategies - Улправда
Is Biohaven Ltd. stock oversold or undervalued2025 Buyback Activity & Low Drawdown Investment Ideas - Улправда
Biohaven (NYSE:BHVN) Shares Up 11.9%Here's Why - MarketBeat
Biohaven expects to raise $125M in stock sale - Hartford Business Journal
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Co - GuruFocus
Biohaven Announces $125 Million Targeted Equity Financing - TipRanks
Biohaven Ltd. Announces $125 Million Share Sale - TradingView — Track All Markets
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a Potential 96% Upside in the Biotech Sector - DirectorsTalk Interviews
Why Biohaven Ltd. Common Shares stock is a strong analyst pick2026 world cup usa national team round of 32 star players transition play knockout prediction preview - ulpravda.ru
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):